MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-08-2022
Albireo Pharma Total Liabilities 2011-2026 | ALBO
Annual Total Liabilities Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 126 M | 104 M | 71.9 M | 62.8 M | 7.97 M | 2.43 M | 1.87 M | 2.63 M | 8.59 M | 10.1 M | 4.43 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 126 M | 1.87 M | 36.7 M |
Quarterly Total Liabilities Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 221 M | 115 M | 113 M | 126 M | 115 M | 106 M | 102 M | 104 M | 104 M | 104 M | 104 M | 71.9 M | 71.9 M | 71.9 M | 71.9 M | 62.8 M | 62.8 M | 62.8 M | 62.8 M | 7.97 M | 7.97 M | 7.97 M | 7.97 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 15.2 M | 1.87 M | 1.87 M | 1.46 M | 2.16 M | 2.63 M | 2.63 M | 2.63 M | 6.57 M | 8.59 M | 8.59 M | 8.59 M | 9.39 M | 10.1 M | 10.1 M | 10.1 M | 4.64 M | 4.43 M | 4.43 M | 4.43 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 221 M | 1.46 M | 43.8 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
705 M | $ 20.15 | -2.68 % | $ 2.54 B |  USA |
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
4.35 M | $ 0.82 | -3.48 % | $ 4.47 M |  China |
 |
Axsome Therapeutics
AXSM
|
602 M | $ 163.7 | -1.61 % | $ 8.14 B | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
390 M | $ 3.72 | -2.75 % | $ 1.11 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 8.52 | -2.46 % | $ 1.39 B | Britain |
 |
Corvus Pharmaceuticals
CRVS
|
6.87 M | $ 17.75 | -0.79 % | $ 852 M | USA |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Certara
CERT
|
494 M | $ 7.16 | 1.49 % | $ 1.15 B | USA |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
36.1 M | $ 25.91 | -3.56 % | $ 694 M | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
82.1 M | $ 0.99 | -3.28 % | $ 72.7 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
150 M | $ 24.0 | 0.5 % | $ 2.93 B | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
7.27 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
387 M | $ 3.19 | -4.64 % | $ 1.14 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
104 M | $ 28.78 | -1.44 % | $ 1.67 B | USA |
 |
Champions Oncology
CSBR
|
28.6 M | $ 6.0 | -1.15 % | $ 82 M | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Завод ДИОД
DIOD
|
195 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
1.04 B | - | - | - | Russia |
 |
Cellectis S.A.
CLLS
|
253 M | $ 3.67 | -3.42 % | $ 116 M | France |
 |
Alector
ALEC
|
263 M | $ 2.11 | -4.75 % | $ 217 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
8.78 M | $ 15.68 | -2.4 % | $ 779 M | Britain |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
7.8 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
15.8 M | $ 4.17 | 0.24 % | $ 296 M | USA |
 |
Teligent, Inc.
TLGT
|
198 M | - | -13.85 % | $ 16.1 M | USA |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
47.4 M | - | - | $ 2.91 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
211 M | $ 14.27 | 2.44 % | $ 5.92 B |  Irlanda |